
    
      The patients with solitary tumor more than 5cm and microvessels invasion after radical
      hepatectomy were randomized to receive adjuvant TACEï¼ˆ1~2 cycles, 4~6 weeks) or follow-up. The
      main endpoint: overall survival (OS), disease-free survival(DFS), and safety were compared
      between this two groups.
    
  